MASTER SUPPLY AGREEMENTMaster Supply Agreement • November 5th, 2020 • Fibrogen Inc • Pharmaceutical preparations
This Master Supply Agreement (the “Agreement”) is entered into and effective as of September 10, 2020 (the “Effective Date”), by and between FibroGen, Inc., a Delaware corporation, having its principal place of business at 409 Illinois Street, San Francisco, California 94158, United States of America (“FibroGen”); and AstraZeneca UK Limited., a company incorporated in England under No. 364842 whose registered office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus CB2 0AA, England (“AstraZeneca”). AstraZeneca and FibroGen may be referred to individually as a “Party”, and collectively as the “Parties”. AstraZeneca and each of its Affiliates shall collectively be referred to herein as “AstraZeneca”. FibroGen and each of its Affiliates shall collectively be referred to herein as “FibroGen”.
Amendment No. 2 To Master Supply AgreementMaster Supply Agreement • November 5th, 2020 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 2 (the “Second Amendment”) is effective as of July 24, 2020 (the “Second Amendment Effective Date”) by and among: FibroGen, Inc. and its Affiliates (collectively, “FibroGen”); and Shanghai SynTheAll Pharmaceutical Co., Ltd (d/b/a “上海合全药业有限公司”) (“Shanghai STA”); and STA Pharmaceutical Hong Kong Limited (d/b/a “合全药业香港有限公司”) (“STA Hong Kong”) (STA Hong Kong, Shanghai STA, and each of their Affiliates are collectively referred to as “STA”). This Second Amendment amends the Master Supply Agreement entered into by and between STA and FibroGen on March 2, 2020 as amended by Amendment No. 1 on May 11, 2020 (collectively, the “Master Supply Agreement”). STA and FibroGen shall be referred to individually herein as a “Party”, and collectively as, the “Parties”. The Master Supply Agreement and this Second Amendment are collectively, “the Agreement”.
LICENSE AGREEMENTLicense Agreement • November 5th, 2020 • Fibrogen Inc • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”), effective, subject to Article 22, upon the Effective Time (as defined in the Agreement and Plan of Merger (the "Merger Agreement") between Fibrogen, Inc., FGIM Corp, Imigen Systems, Inc. (the "Imigen Acquisition") ("Effective Date"), is between the Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization having a principal place of business at 44 Binney Street, Boston, Massachusetts, 02115 (“DFCI”), and FibroGen, Inc., a Delaware corporation having a principal place of business at 225 Gateway Blvd., South San Francisco, CA 94080 (“LICENSEE”).
AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (for the US and Certain Other Territories) between FIBROGEN, INC. and ASTRAZENECA ABDevelopment and Commercialization Agreement • November 5th, 2020 • Fibrogen Inc • Pharmaceutical preparations • California
This Amended and Restated License, Development and Commercialization Agreement (the “Agreement”) is entered into as of October 16, 2014 (the “Execution Date”), and effective as of July 30, 2013 (the “Effective Date”) by and between FibroGen, Inc., a Delaware corporation having its principal place of business at 409 Illinois St., San Francisco, California 94158, United States (“FibroGen”) and AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with offices at Pepparedsleden 1, 431 83 Mölndal, Gothenburg, Sweden (“AstraZeneca”). FibroGen and AstraZeneca are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ContractLicense Agreement • November 5th, 2020 • Fibrogen Inc • Pharmaceutical preparations
[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.
LICENSE AGREEMENTLicense Agreement • November 5th, 2020 • Fibrogen Inc • Pharmaceutical preparations • Florida
This Agreement, made and entered into this 23rd day of May, 1997 (the Effective Date"), by and between the UNIVERSITY OF MIAMI and its SCHOOL OF MEDICINE, having its principal office at 1600 N.W. 10th Avenue, Miami, Florida 33136 (hereinafter “LICENSOR") and FIBROGEN, INC., a corporation duly organized under the laws of Delaware and having its principal office at 260 Littlefield Avenue, South San Francisco, California 94080 and its Affiliates (hereinafter collectively, "FIBROGEN”).
AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (CHINA) between FIBROGEN CHINA ANEMIA HOLDINGS, LTD.; BEIJING FIBROGEN MEDICAL TECHNOLOGY DEVELOPMENT CO., LTD.; FIBROGEN INTERNATIONAL (HONG KONG) LIMITED and ASTRAZENECA AB (PUBL)Fibrogen Inc • November 5th, 2020 • Pharmaceutical preparations • California
This Amended and Restated License, Development and Commercialization Agreement (China) (the “Agreement”) is entered into as of October 16, 2014 (the “Execution Date”) and effective as of July 30, 2013 (the “Effective Date”), by and between FibroGen China Anemia Holdings, Ltd., having a registered office at c/o Ogier Fiduciary Services (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, Cayman Islands KY1-9007 (“FibroGen Cayman”), Beijing FibroGen Medical Technology Development Co., Ltd., a wholly foreign owned limited liability company having its principal place of business at No. 88 Building Kechuang Street 6 Building 2, Floor 4, Room 503, Beijing Economic-Technological Development Area, Beijing, 100000, the People’s Republic of China (“FibroGen WFOE”) and FibroGen International (Hong Kong) Limited, having a registered office at 18th Floor, Edinburgh Tower, The Landmark, 15 Queen's Road Central, Hong Kong (“FibroGen HK”) (FibroGen WFOE, FibroGen Cayman and FibroGen HK, collectiv
AMENDMENT NO. 2 TO RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • November 5th, 2020 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 2 to research and commercialization Agreement ("Amendment") is made and entered into effective as of January 28, 2002 (the "Amendment Date") by and between Medarex, Inc., 707 State Road, Suite 206, Princeton, NJ 08540, GenPharm International Inc., a wholly-owned subsidiary of Medarex, Inc. (together, "Medarex"), and FibroGen, Inc., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FibroPharma, Inc., a wholly-owned subsidiary of FibroGen, Inc. (collectively, "FibroGen"). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).
